CN103055164A - Traditional Chinese medicine composition for treating isolated diastolic hypertension - Google Patents
Traditional Chinese medicine composition for treating isolated diastolic hypertension Download PDFInfo
- Publication number
- CN103055164A CN103055164A CN2012105749027A CN201210574902A CN103055164A CN 103055164 A CN103055164 A CN 103055164A CN 2012105749027 A CN2012105749027 A CN 2012105749027A CN 201210574902 A CN201210574902 A CN 201210574902A CN 103055164 A CN103055164 A CN 103055164A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- chinese medicine
- medicine composition
- treatment
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating isolated diastolic hypertension. The traditional Chinese medicine composition is composed of uncaria, raw eucommia, Chinese taxillus herb, cyathula root and tall gastrodia tuber. Conventional adjuvants are added into the above-mentioned raw materials, and a conventional process is utilized for preparation of a tablet, a capsule, a powder, a soft capsule, etc. The traditional Chinese medicine composition has a substantial therapeutic effect on isolated diastolic hypertension and has no side-effects.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, be specifically related to a kind of Chinese medicine composition for the treatment of isolated diastolic hypertension.
Background technology
Isolated diastolic hypertension (IDH) refers to the hypertension of systolic pressure (SBP)＜140mmHg and diastolic pressure (DBP) 〉=90 mmHg, is a hypotype of hypertension.Research finds that systolic pressure rises with age growth, and diastolic pressure is about the male is 60 years old, and the women reaches the peak about 70 years old, after this slow decreasing.Therefore, isolated systolic hypertension (ISH) ratio significantly increases with advancing age, the isolated diastolic hypertension ratio significantly reduces.
The crowd that sends out well of IDH is youngster, male, obesity, sleep disordered breathing person, the bad life habits person such as especially have smoking, indulge in excessive drinking, do not get enough athletic exercise.
Many systolic pressure and diastolic pressures of studies confirm that are apoplexy and coronary heart disease independent hazard factor.Britain studies have shown that the Prospective Study that 420,000 people carry out, diastolic pressure and apoplexy are very clear and definite linear correlation, even diastolic pressure and apoplexy also are clear and definite positive correlation, the every increase of diastolic pressure 10mmHg within normal range, incidence of stroke increases by 56%, and the coronary heart disease incidence rate increases by 37%.Therefore, the harm of diastolic hypertension should not be underestimated.
Summary of the invention
The invention provides a kind of Chinese medicine composition for the treatment of isolated diastolic hypertension.
The present invention seeks to be achieved through the following technical solutions:
Traditional Chinese medicinal composition raw materials of the present invention consists of:
Ramulus Uncariae Cum Uncis 5-30 weight portion Cortex Eucommiae 5-15 weight portion Herba Taxilli 5-15 weight portion Radix Cyathulae 5-20 weight portion Rhizoma Gastrodiae 1-15 weight portion
Traditional Chinese medicinal composition raw materials composition of the present invention is preferably:
Ramulus Uncariae Cum Uncis 15-30 weight portion Cortex Eucommiae 10-15 weight portion Herba Taxilli 8-12 weight portion Radix Cyathulae 10-15 weight portion Rhizoma Gastrodiae 5-10 weight portion
Traditional Chinese medicinal composition raw materials composition of the present invention is preferably:
Ramulus Uncariae Cum Uncis 12 weight portion Cortex Eucommiae 10 weight portion Herba Taxillis 10 weight portion Radix Cyathulaes 12 weight portion Rhizoma Gastrodiaes 8 weight portions
Traditional Chinese medicinal composition raw materials composition of the present invention is preferably:
Ramulus Uncariae Cum Uncis 14 weight portion Cortex Eucommiae 9 weight portion Herba Taxillis 9 weight portion Radix Cyathulaes 14 weight portion Rhizoma Gastrodiaes 6 weight portions
Traditional Chinese medicinal composition raw materials composition of the present invention is preferably:
Ramulus Uncariae Cum Uncis 11 weight portion Cortex Eucommiae 11 weight portion Herba Taxillis 11 weight portion Radix Cyathulaes 12 weight portion Rhizoma Gastrodiaes 8 weight portions
Chinese medicine composition of the present invention adds conventional adjuvant, according to common process, make tablet, capsule, powder, soft capsule, drop pill, honeyed pill, pill, granule, soft extract with bee honey agent, slow releasing preparation, quick releasing formulation, controlled release preparation, oral liquid, lyophilized injectable powder or ejection preparation.
Chinese medicine composition of the present invention is comprised of Cortex Eucommiae, Herba Taxilli, Radix Cyathulae, Rhizoma Gastrodiae, Ramulus Uncariae Cum Uncis.Cortex Eucommiae is longer than invigorating the liver and kidney, bone and muscle strengthening to effect a permanent cure, and is monarch drug.Minister is with Herba Taxilli, and the master enters liver, kidney channel, and the flat invigorating the liver and kidney of function is to increase the merit of monarch drug; Two medicines share, to the hypertensive soreness of the waist and knees of deficiency of the liver and kindey type, the forgetful patient You Yi of tinnitus.Ramulus Uncariae Cum Uncis, the function suppressing liver-YANG also is ministerial drug, is the principal agent of the partially high headache and dizzy for the treatment of liver-yang.Assistant is with Radix Cyathulae liver and kidney tonifying first, and the liver-yang that draws first rising is descending, treating both the principal and secondary aspects of a disease; The Rhizoma Gastrodiae suppressing liver-YANG is the guiding drug of headache, for making medicine to take stopgap measures simultaneously.All medicines share, treating both the principal and secondary aspects of a disease, YIN and YANG balancing, steadily blood pressure lowering.
Hypertension effect of simple diastolic pressure phase of traditional Chinese medicine composition for treating of the present invention significantly and have no side effect.
The below's experiment and embodiment are used for further specifying but are not limited to the present invention.
Experimental example one: clinical experiment
1 data and method
1.1 physical data
All cases all derive from the Liwan District hospital of traditional Chinese hospital, Guangzhou and Guangzhou City Traditional Chinese Medicine Hospital in December, 2003～2006 year outpatient service in October and inpatient.Include altogether isolated diastolic hypertension patient 90 examples in according to diagnostic criteria, inclusive criteria, exclusion standard.Method according to random digit is divided into test group and matched group at random.Test group 67 examples, male's 22 examples, women's 45 examples, 64.42 ± 12.43 years old age, the course of disease 4.60 ± 4.92 years.Matched group 30 examples, male's 17 examples, women's 13 examples, 74.13 ± 10.00 years old age, the course of disease 7.18 ± 5.81 years.Two groups of data are learned by statistics and are processed no significant difference (p〉0.05), have comparability.
1.2 intervening measure
Test group is taken Chinese medicine composition of the present invention (according to embodiment two preparations), each 120ml, and every day 2 times, warm water takes.Matched group is taken Enalapril (enalapril maleate sheet, every 20mg), each 20mg, every day 2 times, after the meal half an hour warm water delivery service.Be January two groups of courses for the treatment of.
All give less salt, low fat diet during two groups of patient treatments, stop using other blood pressure lowerings, blood fat reducing and affect the medicine of blood pressure, the spirit of taking good care of oneself, suitably movable, avoid exertion.
1.3 observation index
1.3.1 health giving quality index: blood pressure, renin activity (PRA), angiotensinⅡ (A II), aldosterone (ALD) hemorheology, liver function, blood fat.
1.3.2 safety indexes: routine blood test, routine urinalysis, untoward reaction.
1.4 statistical method
Adopt the SAS8.2 statistical software to analyze, ranked data are checked with Wilcoxon, enumeration data X
2Check, measurement data is checked with t.
2 results
2.1 the total effective rate of two groups of blood pressure lowerings relatively
The obvious effective rate of test group blood pressure lowering is 86.57%, and effective percentage is 11.94%, and total effective rate is 95.52%.The obvious effective rate of matched group blood pressure lowering is 80%, and effective percentage 20%, total effective rate are that antihypertensive effect is compared there was no significant difference between 100%, two group, specifically see Table 1.
Table 1 liang group blood pressure lowering effective percentage is (routine %) relatively
Annotate: two groups of curative effects are no difference of science of statistics (p〉0.05) relatively.
2.2 two groups of hemorheology curative effects relatively
The hemorheology value compares there was no significant difference before two groups of patient treatments, specifically sees Table 2.Plasma Viscosity has obvious reduction after the test group treatment, and significant difference (p＜0.05) is arranged; The hemorheology value compares no difference of science of statistics (p＞0.05) between organizing after two groups of treatments, specifically sees Table 3.
The hemorheology value relatively before the table 2 liang group treatment
Annotate: hemorheological numerical value unknown significance difference before two groups of treatments has comparability (p＞0.05).
The Hemorheology curative effect relatively in organizing after the table 3 liang group treatment, between group
Annotate: Plasma Viscosity has obvious reduction (p＜0.05) after the test group treatment as can be seen from Table 3, compares there was no significant difference (p＞0.05) between two groups.
2.3 two groups are improved the blood fat curative effect relatively
The blood fat value compares there was no significant difference before two groups of patient treatments, specifically sees Table 4.Cholesterol, triglyceride, low-density lipoprotein all have obvious reduction after the treatment of control group, and the test group high density lipoprotein obviously raises, but the difference (p＞0.05) of comparing between two groups that there are no significant specifically sees Table 5.
The blood fat value relatively before the table 4 liang group treatment
Annotate: treat front two groups of blood fat numerical value and compare there was no significant difference, have comparability (p＞0.05).
The blood fat and improving curative effect relatively in organizing after the table 5 liang group treatment, between group
Annotate: cholesterol, triglyceride, low-density lipoprotein all have obvious reduction after the treatment of control group, and the test group high density lipoprotein obviously raises, but compare there was no significant difference between two groups (p＞0.05).
2.4 two groups are improved three of hypertension (PRA, A II, ALD) curative effect relatively
PRA, A II, ALD numerical value there was no significant difference have comparability (p＞0.05) before two groups of treatments, specifically see Table 6.The content of angiotensinⅡ (A II) obviously reduces (p＜0.01) after the test group treatment, compares PRA, A II, ALD between two groups and is showed no significant difference (p＞0.05), specifically sees Table 7.
Three values of hypertension relatively before the table 6 liang group treatment
Annotate: three values of hypertension there was no significant difference before two groups of treatments has comparability (p＞0.05).
Curative effect relatively in table 7 liang rear three value groups of hypertension of group treatment, between group
Annotate: the content of angiotensinⅡ (A II) obviously reduces (p＜0.01) after the test group treatment, compares PRA, A II, ALD between two groups and is showed no significant difference (p＞0.05).
2.5 safety analysis
2.5.1 two groups to liver function influence relatively
The liver function value compares there was no significant difference before two groups of patient treatments, specifically sees Table 8.ALT, TBIL, IBIL obviously reduce (p＜0.05) after the test group treatment, compare there was no significant difference (p＞0.05) with matched group, specifically see Table 9.
The liver function value relatively before the table 8 liang group treatment
Annotate: liver function value there was no significant difference before two groups of treatments has comparability (p＞0.05).
The liver function curative effect relatively in organizing after the table 9 liang group treatment, between group
Annotate: ALT, TBIL, IBIL obviously reduce (p＜0.05) after the test group treatment, compare there was no significant difference (p＞0.05) with the Western medicine group.
2.5.2 untoward reaction is observed
Two groups of blood, routine urinalysis check treatment front and back are showed no significant change; All do not find obvious adverse reaction for two groups.
Subordinate embodiment all can realize the effect of above-mentioned experimental example.
Embodiment one:
Ramulus Uncariae Cum Uncis 12g Cortex Eucommiae 10g Herba Taxilli 10g Radix Cyathulae 12g Rhizoma Gastrodiae 8g
Said medicine adds conventional adjuvant according to common process, makes tablet.
Embodiment two:
Ramulus Uncariae Cum Uncis 15g Cortex Eucommiae 10g Herba Taxilli 10g Radix Cyathulae 15g Rhizoma Gastrodiae 10g
Said medicine adds conventional adjuvant according to common process, makes oral liquid.
Embodiment three:
Ramulus Uncariae Cum Uncis 11g Cortex Eucommiae 11g Herba Taxilli 11g Radix Cyathulae 12g Rhizoma Gastrodiae 8g
Said medicine adds conventional adjuvant according to common process, the granulation agent.
Embodiment four:
Ramulus Uncariae Cum Uncis 6g Cortex Eucommiae 13g Herba Taxilli 14g Radix Cyathulae 6g Rhizoma Gastrodiae 13g
Said medicine adds conventional adjuvant according to common process, makes ejection preparation.
Embodiment five:
Ramulus Uncariae Cum Uncis 18g Cortex Eucommiae 7g Herba Taxilli 7g Radix Cyathulae 18g Rhizoma Gastrodiae 13g
Said medicine adds conventional adjuvant according to common process, makes the slow releasing preparation preparation.
Claims (9)
1. Chinese medicine composition for the treatment of isolated diastolic hypertension is characterized in that this traditional Chinese medicinal composition raw materials consists of:
Ramulus Uncariae Cum Uncis 5-30 weight portion Cortex Eucommiae 5-15 weight portion Herba Taxilli 5-15 weight portion Radix Cyathulae 5-20 weight portion Rhizoma Gastrodiae 1-15 weight portion.
2. a kind of Chinese medicine composition for the treatment of isolated diastolic hypertension as claimed in claim 1 is characterized in that this traditional Chinese medicinal composition raw materials consists of:
Ramulus Uncariae Cum Uncis 15-30 weight portion Cortex Eucommiae 10-15 weight portion Herba Taxilli 8-12 weight portion Radix Cyathulae 10-15 weight portion Rhizoma Gastrodiae 5-10 weight portion.
3. a kind of Chinese medicine composition for the treatment of isolated diastolic hypertension as claimed in claim 1 is characterized in that this traditional Chinese medicinal composition raw materials consists of:
Ramulus Uncariae Cum Uncis 12 weight portion Cortex Eucommiae 10 weight portion Herba Taxillis 10 weight portion Radix Cyathulaes 12 weight portion Rhizoma Gastrodiaes 8 weight portions.
4. a kind of Chinese medicine composition for the treatment of isolated diastolic hypertension as claimed in claim 1 is characterized in that this traditional Chinese medicinal composition raw materials consists of:
Ramulus Uncariae Cum Uncis 14 weight portion Cortex Eucommiae 9 weight portion Herba Taxillis 9 weight portion Radix Cyathulaes 14 weight portion Rhizoma Gastrodiaes 6 weight portions.
5. a kind of Chinese medicine composition for the treatment of isolated diastolic hypertension as claimed in claim 1 is characterized in that this traditional Chinese medicinal composition raw materials consists of:
Ramulus Uncariae Cum Uncis 11 weight portion Cortex Eucommiae 11 weight portion Herba Taxillis 11 weight portion Radix Cyathulaes 12 weight portion Rhizoma Gastrodiaes 8 weight portions.
6. such as the Chinese medicine composition of the arbitrary described treatment isolated diastolic hypertension of claim 1-5, it is characterized in that this Chinese medicine composition adds conventional adjuvant, according to common process, make tablet, capsule, powder, soft capsule, drop pill, honeyed pill, pill, granule, soft extract with bee honey agent, slow releasing preparation, quick releasing formulation, controlled release preparation, oral liquid, lyophilized injectable powder or ejection preparation.
7. the preparation method of the Chinese medicine composition for the treatment of isolated diastolic hypertension as claimed in claim 6, it is characterized in that the method is: Chinese medicine composition adds conventional adjuvant, according to common process, make tablet, capsule, powder, soft capsule, drop pill, honeyed pill, pill, granule, soft extract with bee honey agent, slow releasing preparation, quick releasing formulation, controlled release preparation, oral liquid, lyophilized injectable powder or ejection preparation.
8. such as the application of the arbitrary described Chinese medicine composition of claim 1-5 in the medicine for the treatment of isolated diastolic hypertension.
9. such as the application of the arbitrary described Chinese medicine composition of claim 1-5 in improving the medicine of blood fat.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210574902.7A CN103055164B (en) | 2012-12-26 | 2012-12-26 | Traditional Chinese medicine composition for treating isolated diastolic hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210574902.7A CN103055164B (en) | 2012-12-26 | 2012-12-26 | Traditional Chinese medicine composition for treating isolated diastolic hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103055164A true CN103055164A (en) | 2013-04-24 |
| CN103055164B CN103055164B (en) | 2014-08-20 |
Family
ID=48098259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210574902.7A Expired - Fee Related CN103055164B (en) | 2012-12-26 | 2012-12-26 | Traditional Chinese medicine composition for treating isolated diastolic hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103055164B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105434901A (en) * | 2015-12-18 | 2016-03-30 | 吴风平 | Hypertension treating traditional Chinese medicine composition |
| CN107260978A (en) * | 2017-08-16 | 2017-10-20 | 河南科技学院 | A kind of Chinese medicine composition and its production and use |
| CN107485686A (en) * | 2017-07-05 | 2017-12-19 | 庞世斌 | It is a kind of to treat the dizzy sick Chinese medicine composition of wind |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1362241A (en) * | 2001-01-08 | 2002-08-07 | 杨孟君 | Nano gastrodia and sharpleaf gambirplant medicine and its preparation |
| CN1970048A (en) * | 2006-12-12 | 2007-05-30 | 魏发荣 | Chinese medicinal oral liquid for treating hypertension |
| CN101579482A (en) * | 2008-05-15 | 2009-11-18 | 北京北大维信生物科技有限公司 | Medicinal composition for treating hypertension and preparation method thereof |
| CN102258693A (en) * | 2010-05-25 | 2011-11-30 | 湖北神农本草中药饮片有限公司 | Traditional Chinese medicine for treating hypertension |
| CN102671000A (en) * | 2012-05-14 | 2012-09-19 | 成都绿迪科技有限公司 | Oral Chinese patent medicine for treating hypertension |
-
2012
- 2012-12-26 CN CN201210574902.7A patent/CN103055164B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1362241A (en) * | 2001-01-08 | 2002-08-07 | 杨孟君 | Nano gastrodia and sharpleaf gambirplant medicine and its preparation |
| CN1970048A (en) * | 2006-12-12 | 2007-05-30 | 魏发荣 | Chinese medicinal oral liquid for treating hypertension |
| CN101579482A (en) * | 2008-05-15 | 2009-11-18 | 北京北大维信生物科技有限公司 | Medicinal composition for treating hypertension and preparation method thereof |
| CN102258693A (en) * | 2010-05-25 | 2011-11-30 | 湖北神农本草中药饮片有限公司 | Traditional Chinese medicine for treating hypertension |
| CN102671000A (en) * | 2012-05-14 | 2012-09-19 | 成都绿迪科技有限公司 | Oral Chinese patent medicine for treating hypertension |
Non-Patent Citations (5)
| Title |
|---|
| 刘丽: "降压化瘀方治疗舒张期高血压26例疗效观察", 《四川中医》 * |
| 刘丽: "降压化瘀方法治疗舒张期高血压", 《湖北中医杂志》 * |
| 韩学杰 等: "从痰瘀论治高血压病的临床研究", 《中华中医药学会心病分会全国第十二次学术年会暨中华中医药学会心病分会换届选举工作会议论文精选》 * |
| 韩学杰 等: "痰瘀同治、解毒通络法治疗高血压病的动态临床研究", 《中国中医急症》 * |
| 黄斌 等: "中西医结合治疗舒张期高血压疗效观察", 《湖北中医杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105434901A (en) * | 2015-12-18 | 2016-03-30 | 吴风平 | Hypertension treating traditional Chinese medicine composition |
| CN107485686A (en) * | 2017-07-05 | 2017-12-19 | 庞世斌 | It is a kind of to treat the dizzy sick Chinese medicine composition of wind |
| CN107260978A (en) * | 2017-08-16 | 2017-10-20 | 河南科技学院 | A kind of Chinese medicine composition and its production and use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103055164B (en) | 2014-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101632819B (en) | Preparation for resisting suppression of bone marrow after lung cancer chemotherapy | |
| CN104645132B (en) | A kind of Chinese medicine composition that treating diabetic nephropathy, preparation method, Chinese medicine preparation and application | |
| CN102133271B (en) | Medicinal tea for curing gout | |
| CN103055164B (en) | Traditional Chinese medicine composition for treating isolated diastolic hypertension | |
| CN102861201B (en) | Medicine composition for treating diabetes and preparation method thereof | |
| CN103417846A (en) | Hypoglycemic traditional Chinese medicine composition and preparation method thereof | |
| CN104083478A (en) | Compound traditional Chinese medicine for treating hypertension | |
| CN101732585A (en) | Medicinal composition for treating migraine, preparation method and application thereof | |
| CN103417950A (en) | Traditional Chinese medicine composition for preventing and treating obese type 2 diabetes combined dyslipidemia | |
| CN102988779A (en) | Chinese medicine composition for treating hypertensive nephropathy and preparation method and application of Chinese medicine composition | |
| CN103341095B (en) | Clysis liquid used for chronic renal failure | |
| CN102579804B (en) | Chinese medicine for treating stenocardia | |
| CN105982906A (en) | Application of 20(R)-ginsenoside Rg3 in preparing medicines or health products capable of alleviating or/and treating rheumatoid diseases and medicines | |
| CN104352973A (en) | Chinese patent medicine for postpartum depression | |
| CN104740579B (en) | Premenstrual peace piece and its preparation technology | |
| CN108743885A (en) | A kind of Chinese medicine and preparation method thereof for treating Diabetic Macrovascular Complications | |
| CN104687032A (en) | Health caring echinacea health product | |
| CN102772540B (en) | A kind of medicine for the treatment of metabolism syndrome | |
| CN102430040A (en) | Medicament for treating diabetes | |
| CN103040983A (en) | Traditional Chinese medicine for preventing and/or treating premonitory apoplexy and preparation method thereof | |
| CN102283980B (en) | Medicament for treating damp and heat swelling type chronic kidney disease | |
| CN101007114B (en) | An adjuvant drug or health food for tumor patients and preparation thereof | |
| CN102068605B (en) | Traditional Chinese medicine composition for treating hypertension | |
| CN101229272A (en) | Medicine compounds for increasing immunizing-power, preparing method and applications thereof | |
| CN104383441A (en) | Method for preparing Chinese patent medicine for treating postpartum depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140820 Termination date: 20181226 |